Browse MADCAM1

Summary
SymbolMADCAM1
Namemucosal vascular addressin cell adhesion molecule 1
Aliases MACAM1; mucosal addressin cell adhesion molecule-1; MAdCAM-1; hMAdCAM-1; Mucosal addressin cell adhesion mol ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF09085 Adhesion molecule
Function

Cell adhesion leukocyte receptor expressed by mucosal venules, helps to direct lymphocyte traffic into mucosal tissues including the Peyer patches and the intestinal lamina propria. It can bind both integrin alpha-4/beta-7 and L-selectin, regulating both the passage and retention of leukocytes. Isoform 2, lacking the mucin-like domain, may be specialized in supporting integrin alpha-4/beta-7-dependent adhesion strengthening, independent of L-selectin binding.

> Gene Ontology
 
Biological Process GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0007159 leukocyte cell-cell adhesion
GO:0007160 cell-matrix adhesion
GO:0007229 integrin-mediated signaling pathway
GO:0007568 aging
GO:0030198 extracellular matrix organization
GO:0030335 positive regulation of cell migration
GO:0031589 cell-substrate adhesion
GO:0034113 heterotypic cell-cell adhesion
GO:0040017 positive regulation of locomotion
GO:0043062 extracellular structure organization
GO:0043113 receptor clustering
GO:0045123 cellular extravasation
GO:0050900 leukocyte migration
GO:0050901 leukocyte tethering or rolling
GO:0051272 positive regulation of cellular component movement
GO:0051668 localization within membrane
GO:0061756 leukocyte adhesion to vascular endothelial cell
GO:0072657 protein localization to membrane
GO:2000147 positive regulation of cell motility
Molecular Function GO:0005178 integrin binding
GO:0050839 cell adhesion molecule binding
GO:0098631 protein binding involved in cell adhesion
GO:0098634 protein binding involved in cell-matrix adhesion
GO:0098640 integrin binding involved in cell-matrix adhesion
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-1474244: Extracellular matrix organization
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-216083: Integrin cell surface interactions
Summary
SymbolMADCAM1
Namemucosal vascular addressin cell adhesion molecule 1
Aliases MACAM1; mucosal addressin cell adhesion molecule-1; MAdCAM-1; hMAdCAM-1; Mucosal addressin cell adhesion mol ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MADCAM1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MADCAM1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21037100Cervical Intraepithelial NeoplasiaPromote immunity (infiltration)Vascular endothelial expression of mucosal addressin cell adhesion molecule-1, the ligand that supports entry of α(4)β(7)(+) T cells into tissues, colocalized tightly with the distribution of CD8 T cells and was not expressed in persistent dysplastic epithelium.
Summary
SymbolMADCAM1
Namemucosal vascular addressin cell adhesion molecule 1
Aliases MACAM1; mucosal addressin cell adhesion molecule-1; MAdCAM-1; hMAdCAM-1; Mucosal addressin cell adhesion mol ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MADCAM1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.52 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMADCAM1
Namemucosal vascular addressin cell adhesion molecule 1
Aliases MACAM1; mucosal addressin cell adhesion molecule-1; MAdCAM-1; hMAdCAM-1; Mucosal addressin cell adhesion mol ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MADCAM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0160.947
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1560.785
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0920.822
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2210.691
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3110.789
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0990.937
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1080.802
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1080.867
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0960.579
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MADCAM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMADCAM1
Namemucosal vascular addressin cell adhesion molecule 1
Aliases MACAM1; mucosal addressin cell adhesion molecule-1; MAdCAM-1; hMAdCAM-1; Mucosal addressin cell adhesion mol ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MADCAM1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMADCAM1
Namemucosal vascular addressin cell adhesion molecule 1
Aliases MACAM1; mucosal addressin cell adhesion molecule-1; MAdCAM-1; hMAdCAM-1; Mucosal addressin cell adhesion mol ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MADCAM1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MADCAM1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMADCAM1
Namemucosal vascular addressin cell adhesion molecule 1
Aliases MACAM1; mucosal addressin cell adhesion molecule-1; MAdCAM-1; hMAdCAM-1; Mucosal addressin cell adhesion mol ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MADCAM1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMADCAM1
Namemucosal vascular addressin cell adhesion molecule 1
Aliases MACAM1; mucosal addressin cell adhesion molecule-1; MAdCAM-1; hMAdCAM-1; Mucosal addressin cell adhesion mol ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MADCAM1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMADCAM1
Namemucosal vascular addressin cell adhesion molecule 1
Aliases MACAM1; mucosal addressin cell adhesion molecule-1; MAdCAM-1; hMAdCAM-1; Mucosal addressin cell adhesion mol ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MADCAM1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMADCAM1
Namemucosal vascular addressin cell adhesion molecule 1
Aliases MACAM1; mucosal addressin cell adhesion molecule-1; MAdCAM-1; hMAdCAM-1; Mucosal addressin cell adhesion mol ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MADCAM1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.